MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of glioblastoma.
Glioblastoma Multiform (GBM) accounts for 15% of all brain tumors, and is also the most aggressive form. It represents a major public health challenge on a global scale. With an estimated annual incidence of 2 to 3 cases per 100,000 inhabitants, it affects around 250,000 people worldwide every year. Its prognosis remains poor, with a median survival of just 15 months after diagnosis.
Its biological complexity and resistance to conventional treatments make glioblastoma a real therapeutic nightmare. Research is intensifying to decipher the underlying mechanisms of the pathology, and develop new, more effective therapeutic approaches. This is illustrated by the growing number of biotherapies in development targeting this indication.
Epidemiological data
2-3
cases per 100,000 inhabitants in Europe and North America
14,6
months median survival
14,5 %
of all brain tumors
Glioblastoma Market
The global glioblastoma market is currently estimated at $3 billion. It should continue to grow , with a CAGR of between 3% and 10% over the coming years. As in the global drug market, the glioblastoma market is dominated by small molecules, with only 22% of available products being biologics.
Market
3-10%
CAGR
Molecule type
2023 Dynamics
Pipeline of projects targeting Glioblastoma
In terms of molecule types, the ratio is reversed in the pipeline, with a preponderance of biomedicines (64%) . The pipeline of biomedicines targeting glioblastoma is rich, with some 400 molecules in development, and also very varied, with many different therapeutic approaches, and notably many MTIs (41.9%). There are also numerous antibody projects (25.6%).
Pipeline
Types of biologics
Want to find out more?
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources: MabDesign & GlobalData
Date – July 2024
